BioScreening - organic compounds for screening

12.01.2007 NEXUS Biosystems' Universal Store Compound Management System Selected as Key Component of Vanderbilt University's High-Throughput Screening Facility
NEXUS Biosystems announced that Vanderbilt University’s High-Throughput Screening (HTS) Facility has selected the Universal Store to manage its ever-growing collection of synthetic small molecules and natural products. The Universal Store will serve as the main repository for maintaining and managing Vanderbilt’s collection as a part of its basic research and translational drug discovery activities. […]
More bioscreening news...

25.01.2007 SBS 13th Annual Conference & Exhibition
Society for Biomolecular Sciences Presents its 13th Annual Conference & Exhibition Advancing the Science of Drug Discovery: Bridging Research & Development April 15-19, 2007 Palais Des Congres de Montréal Montréal, Canada After the Society's most successful annual event in Seattle this year, professionals from around the globe will want to participate in the next SBS Annual Conference & Exhibition in April 2007. This will be the first spring annual the Society has scheduled. The SBS event, the premier scientific and showcase event in molecular discovery, brings together more than 2,900 professionals, offering a unique opportunity to learn more about the latest innovations, technologies, and research in the drug discovery sciences from all over the world. Session topics include: · Advances in Screening Technologies · Biomarkers: From Bench to Clinic · Compound Management: Challenges & Automation Solutions · Enzyme Targets: Black Box or Whole Cell Assays? · From Gene to Target: Functional Target Validation Strategies · High-Content Cellular Screening · Immunotherapeutics, mAbs & Translational Medicine · Structural Biology: Underpinning Drug Discovery · Systems Biology & High-Throughput Approaches to Screening Native Cells · Target Biology & Screening: GPCRs · Target Biology & Screening: Ion Channels · Toxicity Profiling Using High-Throughput & High-Content Technologies Contact: Marietta Manoni, CMP Conference Manager mmanoni@sbsonline.org Society for Biomolecular Sciences 36 Tamarack Avenue, #348, Danbury, CT 06811, USA Phone: +1 (203) 743-1336 Fax: +1 (203) 748-7557 www.sbsonline.org
More bioscreening news...

19.01.2007 Nanion continues opposition against Molecular Devices patent – "a precautionary measure"
Nanion Technologies GmbH, a supplier of automated, parallel patch-clamp systems based in Munich, Germany, today announced that they would appeal the decision of the European Patent Office (EPO) to uphold the disputed Molecular Devices patent EP 1,040,349.

The appeal is merely a precaution against problems with future developments in the field and it should be realized that the disputed patent has no relevance for Nanion’s currently marketed products such as the Port-a-Patch or the Patchliner. Rather, the disputed patent seeks protection for a well-known physical effect that theoretically can be used to exert electrical force on cells or vesicles.

"All currently marketed planar patch-clamp devices use suction to move cells, not electrical force, which so far has proved unreliable. However, all of them, and many other devices published long before MDC’s patent can produce such electrical forces if enough voltage is applied." explains Nanion's CEO Niels Fertig. Jan Behrends, cofounder and chairman of the board concurs: "In its provisional opinion, the Opposition Division at EPO in Munich, seemed to have understood this point very clearly. We were very surprised that during oral proceedings they moved away from their original opinion, but we're confident that the Board of Appeal, who will really make the final judgement, will reverse that decision."

The disputed patent was originally filed by the Ecole Polytechnique Federale in Lausanne, Switzerland and then taken over by Cytion SA, a start-up company acquired by Molecular Devices in 2001 and shut down shortly after.

Andrea Brüggemann, CSO at Nanion, comments: "Our customers should know that this patent dispute in no way concerns our present planar patch technology, nor indeed those marketed by Molecular Devices. The recent decision, which is open to appeal, is, therefore, not a concern for our core business."

In both academic and industrial settings, Nanion's Port-a-Patch enjoys great popularity as the world's smallest patch clamp device. Furthermore, the Patchliner, Nanion's higher throughput patch-clamp robot, has seen a very successful market entry in 2006. Both in 2005 and 2006 Nanion's products received top ratings in customer surveys run by HTStec.

Nanion Technologies GmbH is a German Private Limited Company and was founded in 2002 as a spin off from Ludwig-Maximilians-University in Munich, Germany.

new | january 2008 | october 2007 | september 2007 | august 2007 | march 2007 | february 2007 | january 2007 | december 2007 | september 2006 | august 2006 | july 2006 | june 2006 | may 2006 | april 2006 | march 2006 | january 2006 | november 2005 | august 2005 | july 2005 | june 2005 | may 2005 | april 2005 | march 2005 | december 2005 | november 2004 | october 2004 | september 2004 | august 2004 | july 2004 | june 2004 | may 2004 | april 2004 | march 2004 | february 2004 | january 2004 | december 2004 | november 2003 | october 2003 | september 2003 | august 2003 | july 2003 | june 2003 | may 2003